Document is current
Any future updates will be listed below
-
Authors
Tran, Ngoc-Anh
Palotai, Miklos
Hanna, Glenn J.
Schoenfeld, Jonathan D.
Bay, Camden P.
Rettig, Eleni M.
Bunch, Paul M.
Juliano, Amy F.
Kelly, Hillary R.
Suh, Chong Hyun
Zander, David A.
Morales Pinzon, Alfredo
Kann, Benjamin H.
Huang, Raymond Y.
Haddad, Robert I.
Guttmann, Charles R. G.
Guenette, Jeffrey P. https://orcid.org/0000-0002-4684-5469
- License Information
-
More Information
Article History
Received: 16 July 2022
Revised: 6 December 2022
Accepted: 27 December 2022
First Online: 31 January 2023
Declarations
:
: The scientific guarantor of this publication is Jeffrey P Guenette MD.
: The authors of this manuscript declare relationships with the following companies:GJH—Consulting and advisory for Naveris.JDS—Research support paid to the institution: Merck, BMS, Regeneron, Debiopharm Consulting / Scientific Advisory Board / Travel fees: Genentech, Immunitas, Debiopharm, BMS, Nanobiotix, Tilos, AstraZeneca, LEK, Catenion, ACI Clinical, Astellas, Stimit. Expert witness fees. Stock options: Immunitas. Equity: Doximity.HRK—Clinical trial funding paid to the institution: Bayer AG.RYH—Research support paid to the institution: BMS, Agios Pharmaceuticals; Paid Consulting: NuVationBio.RIH—Research support paid to the institution: Boehringer Ingelheim, Merck, Briston-Myers Squib, Celgene, AstraZeneca, VentiRx, Genentech, Pfizer, Kura; Leadership: NCCN; Consulting or Advisory Role: Celgene, Merck, Eisai, Bristol-Myers Squib, AstraZeneca, Pfizer, Loxo, Genentech, Immunomic Therapeutics, GSK, Gilead Sciences, Vaccinex, EMD Serono, BioNTech AG, Achilles Therapeutics, Bayer, Mirati Therapeutics; Other: Nanobiotix, ISA Pharmaceuticals.CRGG—Research funding: Sanofi, National Multiple Sclerosis Society, NIH, the International Progressive Multiple Sclerosis Alliance, U.S. Office for Naval Research, Focused Ultrasound Foundation, Qynapse; Travel support: Roche Pharmaceuticals; Consultation fees and travel support: Sintetica SA; Stock: Roche, Novartis, GSK, Alnylam, Protalix Biotherapeutics, Arrowhead Pharmaceuticals, Cocrystal Pharma, Sangamo Therapeutics.JPG—Funded in part by the GE Radiology Research Academic Fellowship through the Association of University Radiologists.All other authors: No conflicts of interest.
: One of the authors has significant statistical expertise.
: Written informed consent was waived by the Institutional Review Board.
: Institutional Review Board approval was obtained.
: Some study subjects or cohorts have been previously reported at ASHNR as in #1 above.
: • retrospective• diagnostic or prognostic study• performed at one institution
